153198-06-2

Basic information

• Product Name: Tert-Butyl 4-(2,2,2-trifluoroacetamido)piperidine-1-carboxylate
• Synonyms: Tert-Butyl 4-(2,2,2-trifluoroacetamido)piperidine-1-carboxylate
• CAS NO: 153198-06-2
• Molecular Formula: C₁₂H₁₉F₃N₂O₃
• Molecular Weight: 296.2860696
• Mol File: 153198-06-2.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Tert-Butyl 4-(2,2,2-trifluoroacetamido)piperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Tert-Butyl 4-(2,2,2-trifluoroacetamido)piperidine-1-carboxylate(153198-06-2)
• EPA Substance Registry System: Tert-Butyl 4-(2,2,2-trifluoroacetamido)piperidine-1-carboxylate(153198-06-2)

Safety Data

• Hazardous Substances Data: 153198-06-2(Hazardous Substances Data)

Upstream product

• 97181-50-5 N-(1-benzyl-4-piperidinyl)-2,2,2-trifluoroacetamide 
• 383-63-1 ethyl trifluoroacetate, 
• 87120-72-7 1-(tert-butoxycarbonyl)-4-aminopiperidine 
• 124830-45-1 tert-butyl 4-aminocyclohexanecarboxylate 
• 50541-93-0 4-amino-1-benzylpiperidine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 97181-51-6 4-trifluoromethylcarbonylamino piperidine 

Downstream Products

• 87120-72-7 1-(tert-butoxycarbonyl)-4-aminopiperidine 
• 309251-30-7 4-(2-fluorophenyl)acetamidopiperidine 
• 153198-07-3 5-bromo-2,3-dimethoxy-N-<1-(tert-butyloxycarbonyl)piperidin-4-yl>benzamide 
• 153198-08-4 5-bromo-2,3-dimethoxy-N-(piperidin-4-yl)benzamide 

Relevant articles and documents

METHODS AND COMPOUNDS FOR TREATMENT OF LYMPHOCYTE-RELATED DISEASES AND CONDITIONS

Methods for treatment of lymphocyte-related diseases and conditions, such as cancer and automimmune diseases, are provided. The methods comprise administration of an effective amount of an oligomer to a patient in need thereof, wherein the oligomer comprises, inter alia, at least one intersubunit linkage having the following structure: wherein R1, L1, X, Y and Z are as defined herein.

Mild deprotection of primary N-(p-toluenesulfonyl) amides with SmI 2 following trifluoroacetylation

A mild deprotection method for notoriously difficult to unmask primary N-(p-toluenesulfonyl) amides was developed during our total synthesis studies toward the marine toxin, gymnodimine. The deprotection occurs at low temperature (-78 °C) under mild conditions by initial activation of the nitrogen with a trifluoroacetyl group, followed by reductive cleavage of the p-toluenesulfonyl group with samarium diiodide. The substrate scope and functional group tolerance of this useful N-S cleavage process, which builds on related cleavage processes of other nitrogen-heteroatom bonds, is explored. Georg Thieme Verlag Stuttgart.

18F-labeled benzamides for studying the dopamine D2 receptor with positron emission tomography

Two series of (N-benzylpiperidin-4-yl)- and (9-azabicyclo[3.3.1]nonan- 3β-yl)benzamides were prepared, and in vitro binding assays were used to measure the affinity of these compounds for dopamine D2, dopamine D3, serotonin 5-HT2, and α2-adrenergic receptors. The results of these studies indicated compounds 23, 26b, and 34 have the selectivity needed for in vivo studies of the D2 (and possibly D3) receptors. 18F-Labeled analogues of 23, 26b and 34 were prepared by N-alkylation of the corresponding desbenzyl precursors with [18F]-4-fluorobenzyl iodide. Preliminary in vivo studies demonstrated that [18F]-23 and [18F]-26b are suitable candidates for further evaluation in positron emission tomography imaging studies. The slow rate of washout of [18F]-34 from nondopaminergic regions and its comparatively high lipophilicity indicates that this compound may not be suitable for imaging studies because of a high level of nonspecific binding.